<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04993794</url>
  </required_header>
  <id_info>
    <org_study_id>5A-Plan IV</org_study_id>
    <nct_id>NCT04993794</nct_id>
  </id_info>
  <brief_title>Additive Anti-inflammatory Action for Critically Ill Patients With Cardiovascular Surgery (Xuebijing) IV</brief_title>
  <official_title>Additive Anti-inflammatory Action for Critically Ill Patients With Cardiovascular Surgery (Xuebijing) IV</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanjing Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      XueBiJing, a Chinese herbal derived therapeutic, has been approved to treat severe infections&#xD;
      (sepsis) in critically ill patients (China Food and Drug Administration; Beijing, China,&#xD;
      Number Z20040033). Cardiopulmonary bypass (CPB) will produce large amounts of inflammatory&#xD;
      mediators and oxygen free radicals, which causes the lipid peroxidation damage and&#xD;
      mononuclear cell migration, thus aggravating organ inflammation and damage. Therefore,&#xD;
      exploring new methods to prevent and alleviate organ injury caused by CPB is an important&#xD;
      topi in clinical practice. However, little knowledge is regarding the effect of Xuebijing&#xD;
      injection on CPB-related organ injury. To answer these questions, the authors conducted this&#xD;
      randomized trial to compare XueBiJing with placebo in critically ill patients with&#xD;
      cardiovascular surgery.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>28-day mortality</measure>
    <time_frame>up to 30 days after surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Highest Sequential Organ Failure Assessment score</measure>
    <time_frame>7 days after randomization</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Cardiovascular Disease</condition>
  <condition>Aortic Dissection</condition>
  <condition>Coronary Artery Disease</condition>
  <condition>Valve Heart Disease</condition>
  <condition>Congenital Heart Disease</condition>
  <condition>Critical Illness</condition>
  <arm_group>
    <arm_group_label>XueBiJing</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>XBJ (Composed of Carthamus tinctorius L., Paeonia Lactifora Pall, Ligusticum wallichii, Salvia miltiorrhiza, Angelica sinensis, etc. Tianjin Chase Sun Pharmaceutical Group, Tianjin, China, batch No. 1603231) 100ml Xuebijing injection every 12 h (q12h) for 60 min</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0.9% saline every 12 h (q12h) for 60 min</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>XueBiJing Injection</intervention_name>
    <description>XueBiJing, specification 10mL/ampule, packaging 10 ampules/container, concentration 0.1g/mL, were manufactured by a Good Manufacturing Practice certified company in China (Tianjin Chase Sun Pharmaceutical Co., Tianjin, China; China lot number 1304291, 1401091 and, 1501261). Generally, the treatment duration of the study was at least 5 days.</description>
    <arm_group_label>XueBiJing</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>Same saline dose as XueBiJing injection is taken intravenously.</description>
    <arm_group_label>Normal saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients who received cardiovascular surgery fulfilled three or more of the following&#xD;
             criteria:&#xD;
&#xD;
               -  Pao2/Fio2 ratio less than or equal to 250mm Hg,&#xD;
&#xD;
               -  Respiratory rate greater than or equal to 30 breaths/min,&#xD;
&#xD;
               -  Blood urea nitrogen greater than 20mg/dL,&#xD;
&#xD;
               -  WBC count &lt; 4,000 cells/mm3 or &gt;15 000 cells/mm3 not due to other causes,&#xD;
&#xD;
               -  Core temperature &lt; 36°C or &gt;38.5°C,&#xD;
&#xD;
               -  Receiving treatment with vasopressors at therapeutic doses after adequate fluid&#xD;
                  resuscitation,&#xD;
&#xD;
               -  radiographic findings of new pulmonary infiltrate(s).&#xD;
&#xD;
          2. Agree to participate in the study and sign the informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant and lactating women.&#xD;
&#xD;
          2. Allergic to Xuebijing and its ingredients, or have severe allergies.&#xD;
&#xD;
          3. Mental illness with poor compliance.&#xD;
&#xD;
          4. Severe primary disease (active pulmonary tuberculosis, asthma, cystic pulmonary&#xD;
             fibrosis, pulmonary sarcoidosis, pulmonary interstitial fibrosis, unresectable tumors,&#xD;
             blood diseases, Alzheimer s disease, or HIV).&#xD;
&#xD;
          5. Participation in other clinical trials in the previous 30 days.&#xD;
&#xD;
          6. Patients who are unsuitable for participation or unable to participate in this trial&#xD;
             according to the judgment of the investigators (existing risk of potential medical&#xD;
             disputes, and severe heart failure limiting the amount of liquid intake).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hong Liu, MD</last_name>
    <phone>18801281613</phone>
    <email>DR.HONGLIU@FOXMAIL.COM</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sheng Zhao, MD</last_name>
    <phone>02568303105</phone>
    <email>zhaosheng0824@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The first affiliated hospital of nanjing medical university</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hong Liu, MD</last_name>
      <phone>188012181613</phone>
      <email>dr.hongliu@foxmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 29, 2021</study_first_submitted>
  <study_first_submitted_qc>August 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 6, 2021</study_first_posted>
  <last_update_submitted>August 9, 2021</last_update_submitted>
  <last_update_submitted_qc>August 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nanjing Medical University</investigator_affiliation>
    <investigator_full_name>Hong Liu</investigator_full_name>
    <investigator_title>Principal Investigator of Cardiovascular Surgery</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Heart Defects, Congenital</mesh_term>
    <mesh_term>Aneurysm, Dissecting</mesh_term>
    <mesh_term>Heart Valve Diseases</mesh_term>
    <mesh_term>Critical Illness</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

